0001493152-22-022357.txt : 20220812 0001493152-22-022357.hdr.sgml : 20220812 20220812161535 ACCESSION NUMBER: 0001493152-22-022357 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220811 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220812 DATE AS OF CHANGE: 20220812 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Guardion Health Sciences, Inc. CENTRAL INDEX KEY: 0001642375 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474428421 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38861 FILM NUMBER: 221160252 BUSINESS ADDRESS: STREET 1: 2925 RICHMOND AVENUE STREET 2: SUITE 1200 CITY: HOUSTON STATE: TX ZIP: 77098 BUSINESS PHONE: (800) 873-5141 MAIL ADDRESS: STREET 1: 2925 RICHMOND AVENUE STREET 2: SUITE 1200 CITY: HOUSTON STATE: TX ZIP: 77098 FORMER COMPANY: FORMER CONFORMED NAME: Guardion Health Sciences, LLC DATE OF NAME CHANGE: 20150513 8-K 1 form8-k.htm
0001642375 false 0001642375 2022-08-11 2022-08-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 11, 2022

 

GUARDION HEALTH SCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-38861   47-4428421

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

2925 Richmond Avenue, Suite 1200

Houston, Texas 77098

(Address of principal executive offices, including zip code)

 

Registrant’s telephone number, including area code: (800) 873-5141

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   GHSI   The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 2.02. Results of Operations and Financial Condition.

 

On August 11, 2022, Guardion Health Sciences, Inc. issued a press release announcing its financial results for the three months and six months ended June 30, 2022. A copy of the press release is furnished herewith as Exhibit 99.1.

 

The information included herein and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits

 

99.1   Press Release Dated August 11, 2022
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 -2- 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  GUARDION HEALTH SCIENCES, INC.
Date: August 12, 2022    
  By: /s/ Bret Scholtes
  Name:  Bret Scholtes
  Title: Chief Executive Officer

 

 -3- 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1 

 

Guardion Health Sciences Announces Financial Results

for the Quarter Ended June 30, 2022

 

Viactiv® Product Line contributes to Highest Quarterly Revenue in

Company History of approximately $3.275 Million,

Shows Significant Revenue Growth from Prior Quarter

 

HOUSTON, TEXAS – August 11, 2022 (GLOBE NEWSWIRE) – Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced its financial results for the quarter ended June 30, 2022. The Company also provided a corporate update to stockholders.

 

The financial highlights presented below were materially impacted by the Company’s June 1, 2021 acquisition of the Viactiv® line of supplement chews for bone health and other applications, which are profitably marketed through many of the nation’s largest retailers, including, among others, Walmart (retail and online), Target and Amazon. The acquisition significantly transformed the business and operations of the Company during 2022 as compared to 2021, such that comparisons of the three months ended June 30, 2022 to the three months ended June 30, 2021 demonstrate the substantial impact that this acquisition has had on the Company’s results of operations.

 

Financial highlights for the three months ended June 30, 2022 included the following:

 

  ●  Net revenues were $3,275,213 for the three months ended June 30, 2022, as compared to net revenues of $1,223,720 for the three months ended June 30, 2021. Net revenues for the three months ended June 30, 2021 included only one month of revenues from the Viactiv® product line, as compared to a full three months of revenues from the Viactiv® product line for the three months ended June 30, 2022.
     
  ● Net revenues for the three months ended June 30, 2022 were $3,275,213, as compared to net revenues of $2,384,619 for the three months ended March 31, 2022, an increase of $890,594 or 37.3%.
     
  ● Gross profit was $1,399,544 for the three months ended June 30, 2022, as compared to gross profit of $558,501 for the three months ended June 30, 2021, reflecting gross margins of 42.7% and 45.6%, respectively. The primary reason for the 2.9 percentage point decrease in gross margin for the three months ended June 30, 2022 related to an impairment charge of $109,363 in such period for out-of-date product packaging materials.
     
  ● Gross profit was $1,399,544 for the three months ended June 30, 2022, as compared to gross profit of $1,096,457 for the three months ended March 31, 2022, reflecting gross margins of 42.7% and 46.0%, respectively. The primary reason for the 3.3 percentage point decrease in gross margin for the three months ended June 30, 2022 related to an impairment charge of $109,363 in such period for out-of-date product packaging materials.

 

-1-
 

 

  ● Loss from operations was $(1,711,578) for the three months ended June 30, 2022, as compared to a loss from operations of $(4,540,554) for the three months ended June 30, 2021. The loss from operations for the three months ended June 30, 2021 included $2,103,680 of transaction costs related to the 2021 acquisition of the Viactiv® product line.
     
  ● Basic and diluted net loss per share for the three months ended June 30, 2022 was $(0.03), as compared to $(0.19) for the three months ended June 30, 2021, based on 61,553,137 weighted average common shares outstanding for the three months ended June 30, 2022, as compared to 24,426,993 weighted average common shares outstanding for the three months ended June 20, 2021.

 

Financial highlights for the six months ended June 30, 2022 included the following:

 

  ● Net revenues were $5,659,832 for the six months ended June 30, 2022, as compared to net revenues of $1,457,017 for the six months ended June 30, 2021. Net revenues for the six months ended June 30, 2021 included only one month of revenues from the Viactiv® product line, as compared to a full six months of revenues from the Viactiv® product line for the six months ended June 30, 2022.
     
  ● Gross profit was $2,496,001 for the six months ended June 30, 2022, as compared to gross profit of $658,762 for the six months ended June 30, 2021, reflecting gross margins of 44.1% and 45.2%, respectively. The primary reason for the 1.1 percentage point decrease in gross margin for the six months ended June 30, 2022 related to an impairment charge of $109,363 in such period for out-of-date product packaging materials.
     
  ● Loss from operations was $(4,331,626) for the six months ended June 30, 2022, as compared to a loss from operations of $(7,210,079) for the six months ended June 30, 2021. The loss from operations for the six months ended June 30, 2021 included $2,103,680 of transaction costs related to the 2021 acquisition of the Viactiv® product line
     
  ● Basic and diluted net loss per share for the six months ended June 30, 2022 was $(0.09), as compared to $(0.31) for the six months ended June 30, 2021, based on 50,462,141 weighted average common shares outstanding for the six months ended June 30, 2022, as compared to 22,897,683 weighted average common shares outstanding for the six months ended June 20, 2021.
     
  ● Net cash used in operations was $(4,800,765) for the six months ended June 30, 2022, as compared to $(7,285,354) for the six months ended June 30, 2021.
     
  ● In February 2022, the Company completed a public offering of shares of common stock, Class A Warrants and Class B Warrants, generating gross proceeds of $11,100,000 and net proceeds, after deducting offering expenses, of $9,968,939. Included in the offering were net proceeds of $1,134,040 from the exercise of warrants.

 

-2-
 

 

  ● As of June 30, 2022, the Company had cash and short-term investments of $14,231,309 and working capital of $17,406,114.

 

Additional significant events that occurred during the three months and six months ended June 30, 2022 and subsequently included the following:

 

  ● The Company’s new Omega Boost Gel Bites, the first expansion of the Viactiv® brand since its acquisition in June 2021, were introduced on the Company’s Shopify website during the three months ended March 31, 2022 and subsequently made available on Amazon.com during the three months ended June 30, 2022. The 1,200 mg Omega-3 Gel Bites serving is designed to provide total body support, including cardiovascular, brain, joint, and eye health.
     
  ● The Company entered into an agreement with OmegaQuant Laboratories, an independent, CLIA-certified laboratory located in Sioux Falls, South Dakota, that offers an extensive suite of clinical tests to researchers, clinicians and the public, including Omega-3 Index, Vitamin D, Prenatal DHA and Mother’s Milk DHA testing. OmegaQuant Laboratories has been retained to conduct further studies on the impact of Omega Boost Gel Bites on overall health. OmegaQuant Laboratories performs fatty acid analysis for commercial and academic research collaborators and for consumers interested in monitoring their nutritional status in both blood and breast milk. The Omega-3 Index tests measure all the fatty acids in the blood, and reports levels of all 24 fatty acids, as well as the Omega-3 index, Ratios, and the Trans Fat Index.

 

Bret Scholtes, Guardion’s President and Chief Executive Officer, commented:

 

“We reported our highest quarterly revenue in Guardion’s history in the second quarter of 2022 despite continued supply chain constraints that prevented us from fully restocking one of our largest legacy retailers. These results were encouraging, and I remain optimistic for the future of Guardion despite the currently challenging macro environment. Additionally, I am very pleased with the quarter-over-quarter growth in revenues we experienced in the second quarter of 2022 as compared to the first quarter of 2022. The approximately 37% increase in revenues in the second quarter of 2022, as compared to the first quarter of 2022, was attributable to a combination of factors, including additional Viactiv® calcium chew inventory, the recent launch of our new Omega Boost Gel Bites, and our focused marketing activities. We are optimistic that, as the supply constraints begin to improve, we should see further increases in revenues.”

 

“Our focus on building a strong foundation for our business, and demonstrating growth and commercial success from that foundation, is continuing, and we believe that the Company’s improved financial performance in the second quarter and six months of 2022 demonstrates that focus. Our June 2021 acquisition of the Viactiv® product line is fueling the increase in our revenues in 2022, both quarter-over-quarter and year-over-year. We also significantly reduced the operating loss during the second quarter of 2022.”

 

-3-
 

 

“We are continuing our focus on achieving three key objectives – demonstrating commercial success, strengthening our commercial engine, and strengthening our clinical nutrition strategy – as we seek to maximize stockholder value by acquiring, developing and marketing a portfolio of science-based, clinically supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients.”

 

“We have continued to actively work toward the fulfillment of these key objectives through increased availability of our calcium chews, expanded sales channels through the launch of a direct-to-consumer eCommerce capability on our website viactiv.com, the introduction of Omega Boost Gel Bites and the launch on our website, followed by the launch on Amazon. We are working to further expand our distribution of existing products, as well as to introduce additional products.”

 

“Concurrently, we continue to develop our brand strategy and, as stated, expand our sales channels, while also focusing on ensuring that scientific support for our products meets our high standards, as exemplified by our recent agreement with OmegaQuant Laboratories to provide high quality professional studies regarding Omega Boost Gel Bites. In the meantime, we look to continue to develop and/or acquire new products that fit into our existing strategy, while also constantly evaluating our existing business lines to ensure they continue to meet our overall strategies.”

 

“We believe our cash resources remain sufficient to advance the Company’s strategy to build a vital clinical nutrition company with recognized brands and consumer trust. We continue to appreciate our stockholders’ patience as we embark on these important strategic initiatives and we look forward to reporting our continuing progress to you,” concluded Mr. Scholtes.

 

Financial Results

 

Additional information with respect to the Company’s business, operations and financial condition as of and for the quarter ended June 30, 2022 is contained in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2022, which has been filed with the U.S. Securities and Exchange Commission (the “SEC”) at www.sec.gov.

 

About Guardion Health Sciences, Inc.

 

Guardion Health Sciences, Inc. (Nasdaq: GHSI), is a clinical nutrition company that offers a portfolio of science-based, clinically supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients. The Company’s combination of expertise and scientifically supported products is the foundation of Guardion’s growing position within the clinical nutrition marketplace. Information and risk factors with respect to Guardion and its business may be obtained in the Company’s filings with the SEC at www.sec.gov.

 

-4-
 

 

Forward-Looking Statement Disclaimer

 

With the exception of the historical information contained in this news release, the matters described herein may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements contain information about our expectations, beliefs, plans or intentions regarding our product development and commercialization efforts, research and development efforts, business, financial condition, results of operations, strategies or prospects, and other similar matters. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” “hopes” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements are based on management’s current expectations and assumptions about future events, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict, and involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company’s ability to raise sufficient financing to implement its business plan, the integration of new management team members, the implementation of new financial, management, accounting and business software systems, the integration of the Viactiv acquisition and possibly additional acquisition targets, the impact of the Covid-19 pandemic, supply chain disruptions, inflation and a potential recession on the Company’s business, operations and the economy in general, the Company’s ability to successfully develop and commercialize its proprietary products and technologies, and the Company’s ability to maintain compliance with Nasdaq’s listing requirements. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Investor Relations Contact:

 

CORE IR

Scott Arnold

516-222-2560

scotta@coreir.com

 

Media Relations Contact:

 

Jules Abraham

Director of Public Relations

CORE IR

917-885-7378

julesa@coreir.com

 

-5-

 

 EX-101.SCH 3 ghsi-20220811.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 ghsi-20220811_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 ghsi-20220811_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Cover
Aug. 11, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 11, 2022
Entity File Number 001-38861
Entity Registrant Name GUARDION HEALTH SCIENCES, INC.
Entity Central Index Key 0001642375
Entity Tax Identification Number 47-4428421
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 2925 Richmond Avenue
Entity Address, Address Line Two Suite 1200
Entity Address, City or Town Houston
Entity Address, State or Province TX
Entity Address, Postal Zip Code 77098
City Area Code (800)
Local Phone Number 873-5141
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol GHSI
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 7 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001642375 2022-08-11 2022-08-11 iso4217:USD shares iso4217:USD shares 0001642375 false 8-K 2022-08-11 GUARDION HEALTH SCIENCES, INC. DE 001-38861 47-4428421 2925 Richmond Avenue Suite 1200 Houston TX 77098 (800) 873-5141 false false false false Common Stock, par value $0.001 per share GHSI NASDAQ true false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://guardionhealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-1.htm ghsi-20220811.xsd ghsi-20220811_lab.xml ghsi-20220811_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "ghsi-20220811_lab.xml" ] }, "presentationLink": { "local": [ "ghsi-20220811_pre.xml" ] }, "schema": { "local": [ "ghsi-20220811.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "GHSI", "nsuri": "http://guardionhealth.com/20220811", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-08-11to2022-08-11", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://guardionhealth.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-08-11to2022-08-11", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 14 0001493152-22-022357-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-022357-xbrl.zip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‡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